BRCA2-related cancer predisposition

Summary

BRCA2-related cancer predisposition (MONDO:0700269) is a cancer caused by BRCA2 (GenCC Definitive), with 4 cohort genes (1 CIViC-evidence somatic driver; 1,000 ClinVar predisposition records).

At a glance

• Classification: Cancer
• Causal gene: BRCA2 (GenCC Definitive)
• Cohort genes: 4
• ClinVar variants: 1,000

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	BRCA2-related cancer predisposition
Mondo ID	MONDO:0700269
GARD	0026409
Is cancer (heuristic)	yes

Data availability: 1,000 ClinVar variants · 68 ClinGen variant curations · 1 GenCC gene-disease record.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary neoplastic syndrome › BRCA2-related cancer predisposition

Related subtypes (116): mosaic variegated aneuploidy syndrome, tuberous sclerosis, hereditary breast ovarian cancer syndrome, hereditary multiple osteochondromas, nevoid basal cell carcinoma syndrome, leukemia, chronic lymphocytic, susceptibility to, 2, blue rubber bleb nevus, cherubism, Beckwith-Wiedemann syndrome, multiple self-healing squamous epithelioma, erythroleukemia, familial, susceptibility to, goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, hyperparathyroidism 2 with jaw tumors, Kaposi sarcoma, susceptibility to, hereditary leiomyomatosis and renal cell cancer, susceptibility to uveal melanoma, melanoma and neural system tumor syndrome, nasopharyngeal carcinoma, susceptibility to, 2, WAGR syndrome, neuroblastoma, susceptibility to, 1, Rothmund-Thomson syndrome, mismatch repair cancer syndrome 1, Wiskott-Aldrich syndrome, N syndrome, hereditary thrombocytopenia and hematologic cancer predisposition syndrome, prostate cancer/brain cancer susceptibility, Brooke-Spiegler syndrome, pancreatic cancer, susceptibility to, 1, Carney-Stratakis syndrome, nasopharyngeal carcinoma, susceptibility to, 1, ovarian cancer, susceptibility to, 1, colorectal cancer, susceptibility to, 1, lung cancer susceptibility 1, leukemia, chronic lymphocytic, susceptibility to, 1, Kostmann syndrome, colorectal cancer, susceptibility to, 2, colorectal cancer, susceptibility to, 3, colorectal cancer, susceptibility to, 5, colorectal cancer, susceptibility to, 6, colorectal cancer, susceptibility to, 7, leukemia, chronic lymphocytic, susceptibility to, 3, leukemia, chronic lymphocytic, susceptibility to, 4, leukemia, chronic lymphocytic, susceptibility to, 5, lung cancer susceptibility 3, colorectal cancer, susceptibility to, 8, colorectal cancer, susceptibility to, 9, colorectal cancer, susceptibility to, 10, colorectal cancer, susceptibility to, 11, lung cancer susceptibility 4, neuroblastoma, susceptibility to, 3, neuroblastoma, susceptibility to, 4, neuroblastoma, susceptibility to, 5, neuroblastoma, susceptibility to, 6, leukemia, acute lymphocytic, susceptibility to, 1, leukemia, acute lymphocytic, susceptibility to, 2, lung cancer susceptibility 5, BAP1-related tumor predisposition syndrome, familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome, Maffucci syndrome, basal cell carcinoma, susceptibility to, 7, colorectal cancer, susceptibility to, 12, leukemia, acute lymphoblastic, susceptibility to, 3, cholangiocarcinoma, susceptibility to, progeroid features-hepatocellular carcinoma predisposition syndrome, neuroblastoma, susceptibility to, 7, DDX41-related hematologic malignancy predisposition syndrome, nasopharyngeal carcinoma, susceptibility to, 3, familial isolated hyperparathyroidism, intestinal polyposis syndrome, dyskeratosis congenita, familial rhabdoid tumor, multiple endocrine neoplasia, hereditary pheochromocytoma-paraganglioma, PTEN hamartoma tumor syndrome, familial multiple fibrofolliculoma, hereditary retinoblastoma, familial atypical multiple mole melanoma syndrome, hereditary nonpolyposis colon cancer, Li-Fraumeni syndrome, Cobb syndrome, neurofibromatosis, susceptibility to familial cutaneous melanoma, pancreatic cancer, susceptibility to, 5, leukemia, acute myeloid, susceptibility to, diffuse gastric and lobular breast cancer syndrome with or without cleft lip and/or palate, glioma susceptibility, hemangioma, capillary infantile, susceptibility to, CDH1-related diffuse gastric and lobular breast cancer syndrome, NTHL1-deficiency tumor predisposition syndrome, SAMD9-related spectrum and myeloid neoplasm risk, neuroblastoma, susceptibility to, 2, BARD1-related cancer predisposition, BRCA1-related cancer predisposition, ATM-related cancer predisposition, CHEK2-related cancer predisposition, PALB2-related cancer predisposition, RAD51C-related cancer predisposition, RAD51D-related cancer predisposition, Li-fraumeni-like syndrome, breast cancer, familial, susceptibility to, 1, breast cancer, familial, susceptibility to, 2, breast cancer, familial, susceptibility to, 3, colorectal cancer, susceptibility to, 4, colorectal cancer, susceptibility to, on chromosome 15, ovarian cancer, familial, susceptibility to, 1, ovarian cancer, familial, susceptibility to, 2, ovarian cancer, familial, susceptibility to, 3, inherited hematologic cancer-predisposing syndrome, mosaic neurofibromatosis/schwannomatosis, tumor predisposition syndrome 2, prostate cancer, hereditary, X-linked 3, follicular lymphoma, susceptibility to, GPR161-related medulloblastoma predisposition, SAMD9L-related spectrum and myeloid neoplasm risk, HAVCR2-related cancer predisposition, EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition

Subtypes (3): breast-ovarian cancer, familial, susceptibility to, 2, glioma susceptibility 3, pancreatic cancer, susceptibility to, 2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

600 retrieved; paginated sample, class counts are floors:

240 conflicting classifications of pathogenicity, 122 likely benign, 96 pathogenic, 87 uncertain significance, 30 benign, 15 likely pathogenic, 8 pathogenic/likely pathogenic, 2 benign/likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
1069017	NM_000059.4(BRCA2):c.156_157insGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGACACCATCCTGGCTAGCACGGTGAAACCCCATCTCTACTAAAAATACAACAAATTAGCCGGGCGTGGTGGCGGGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACCTGGGAGACGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAATCTGAACAT (p.Lys53delinsAlaGlyArgGlyGlySerArgLeuTer)	BRCA2	Pathogenic	criteria provided, multiple submitters, no conflicts
1076700	NM_000059.4(BRCA2):c.9699T>A (p.Cys3233Ter)	BRCA2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
126203	NM_000059.4(BRCA2):c.9227G>T (p.Gly3076Val)	BRCA2	Pathogenic	reviewed by expert panel
126217	NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs)	BRCA2	Pathogenic	reviewed by expert panel
141509	NM_000059.4(BRCA2):c.6816_6820del (p.Gly2274fs)	BRCA2	Pathogenic	reviewed by expert panel
142095	NM_000059.4(BRCA2):c.8954-1_8955delinsAA	BRCA2	Pathogenic	reviewed by expert panel
142868	NM_000059.4(BRCA2):c.2059_2063del (p.Leu686_Asp687insTer)	BRCA2	Pathogenic	reviewed by expert panel
142998	NM_000059.4(BRCA2):c.476-4_476-1delinsT	BRCA2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1454980	NM_000059.4(BRCA2):c.3125dup (p.Leu1042fs)	BRCA2	Pathogenic	criteria provided, multiple submitters, no conflicts
186927	NM_000059.4(BRCA2):c.3353_3355del (p.Leu1118_Glu1119delinsTer)	BRCA2	Pathogenic	reviewed by expert panel
187740	NM_000059.4(BRCA2):c.2612C>G (p.Ser871Ter)	BRCA2	Pathogenic	reviewed by expert panel
220844	NM_000059.4(BRCA2):c.3201del (p.Val1068fs)	BRCA2	Pathogenic	reviewed by expert panel
225754	NM_000059.4(BRCA2):c.8566_8567delinsC (p.Glu2856fs)	BRCA2	Pathogenic	reviewed by expert panel
230582	NM_000059.4(BRCA2):c.2641G>T (p.Glu881Ter)	BRCA2	Pathogenic	reviewed by expert panel
230991	NM_000059.4(BRCA2):c.5334_5340del (p.Asn1778fs)	BRCA2	Pathogenic	reviewed by expert panel
234524	NM_000059.4(BRCA2):c.4651C>T (p.Gln1551Ter)	BRCA2	Pathogenic	reviewed by expert panel
236835	NM_000059.4(BRCA2):c.2095C>T (p.Gln699Ter)	BRCA2	Pathogenic	reviewed by expert panel
254556	NM_000059.4(BRCA2):c.5281G>T (p.Gly1761Ter)	BRCA2	Pathogenic	reviewed by expert panel
266609	NM_000059.4(BRCA2):c.1097T>G (p.Leu366Ter)	BRCA2	Pathogenic	reviewed by expert panel
266703	NM_000059.4(BRCA2):c.2490_2491insT (p.Val831fs)	BRCA2	Pathogenic	reviewed by expert panel
266918	NM_000059.4(BRCA2):c.6052_6053del (p.Lys2017_Ser2018insTer)	BRCA2	Pathogenic	reviewed by expert panel
266953	NM_000059.4(BRCA2):c.6502G>T (p.Gly2168Ter)	BRCA2	Pathogenic	reviewed by expert panel
266960	NM_000059.4(BRCA2):c.6536_6537insA (p.Leu2180fs)	BRCA2	Pathogenic	reviewed by expert panel
266970	NM_000059.4(BRCA2):c.6676G>T (p.Glu2226Ter)	BRCA2	Pathogenic	reviewed by expert panel
267094	NM_000059.4(BRCA2):c.8517C>A (p.Tyr2839Ter)	BRCA2	Pathogenic	reviewed by expert panel
267157	NM_000059.4(BRCA2):c.9357_9360del (p.Ile3120fs)	BRCA2	Pathogenic	reviewed by expert panel
267172	NM_000059.4(BRCA2):c.9789_9790del (p.Asn3264fs)	BRCA2	Pathogenic	reviewed by expert panel
3236852	NM_000059.4(BRCA2):c.8085del (p.Ser2695_Leu2696insTer)	BRCA2	Pathogenic	criteria provided, multiple submitters, no conflicts
3386239	NM_000059.4(BRCA2):c.3090del (p.Phe1031fs)	BRCA2	Pathogenic	criteria provided, single submitter
3386251	NM_000059.4(BRCA2):c.6052del (p.Ser2018fs)	BRCA2	Pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 13 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
BRCA2	Definitive	Autosomal dominant	BRCA2-related cancer predisposition	13

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
TMEM132E	Orphanet:90636	Rare autosomal recessive non-syndromic sensorineural deafness type DFNB

Cohort genes → proteins

4 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	gencc,clinvar
TMEM132E	HGNC:26991	ENSG00000181291	Q6IEE7	Transmembrane protein 132E	clinvar
NALF1	HGNC:33877	ENSG00000204442	B1AL88	NALCN channel auxiliary factor 1	clinvar
LINC00373	HGNC:42695	ENSG00000231019		long intergenic non-protein coding RNA 373	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
TMEM132E	Transmembrane protein 132E	Required for normal inner ear hair cell function and hearing.
NALF1	NALCN channel auxiliary factor 1	Auxillary component of the NALCN sodium channel complex, a channel that regulates the resting membrane potential and controls neuronal excitability.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 4 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	4	1.8×	0.097

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
TMEM132E	Other/Unknown	no		TMEM132, TMEM132_N, TMEM132_C
NALF1	Other/Unknown	no		NALCN_aux_factor_1/2
LINC00373	Other/Unknown	no

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
secondary oocyte	1
ventricular zone	1
cerebellar hemisphere	1
kidney epithelium	1
right hemisphere of cerebellum	1
Brodmann (1909) area 23	1
buccal mucosa cell	1
endothelial cell	1
bone marrow	1
lymph node	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
TMEM132E	169	tissue_specific	yes	kidney epithelium, right hemisphere of cerebellum, cerebellar hemisphere
NALF1	187	broad	marker	endothelial cell, Brodmann (1909) area 23, buccal mucosa cell
LINC00373	32		yes	male germ line stem cell (sensu Vertebrata) in testis, lymph node, bone marrow

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRCA2	4,839
NALF1	662
TMEM132E	653
LINC00373	0

Structural data

PDB: 2 · AlphaFold-only: 1 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA2	P51587	14
NALF1	B1AL88	5

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
TMEM132E	Q6IEE7	72.44

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 27. Enrichment computed across 4 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Impaired BRCA2 translocation to the nucleus	1	3806.7×	0.004	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	3806.7×	0.004	BRCA2
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	951.7×	0.005	BRCA2
HDR through MMEJ (alt-NHEJ)	1	878.5×	0.005	BRCA2
Diseases of DNA Double-Strand Break Repair	1	815.7×	0.005	BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	815.7×	0.005	BRCA2
Resolution of D-Loop Structures	1	634.4×	0.005	BRCA2
Diseases of DNA repair	1	571.0×	0.005	BRCA2
Impaired BRCA2 binding to PALB2	1	456.8×	0.005	BRCA2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	423.0×	0.005	BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	423.0×	0.005	BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	423.0×	0.005	BRCA2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	393.8×	0.005	BRCA2
Homologous DNA Pairing and Strand Exchange	1	380.7×	0.005	BRCA2
Homology Directed Repair	1	308.6×	0.005	BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	308.6×	0.005	BRCA2
Impaired BRCA2 binding to RAD51	1	308.6×	0.005	BRCA2
Resolution of D-loop Structures through Holliday Junction Intermediates	1	300.5×	0.005	BRCA2
Meiosis	1	285.5×	0.005	BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	1	271.9×	0.005	BRCA2
DNA Double-Strand Break Repair	1	248.3×	0.005	BRCA2
Reproduction	1	190.3×	0.006	BRCA2
HDR through Homologous Recombination (HRR)	1	190.3×	0.006	BRCA2
Meiotic recombination	1	129.8×	0.009	BRCA2
DNA Repair	1	98.5×	0.011	BRCA2
Cell Cycle	1	36.0×	0.029	BRCA2
Disease	1	13.1×	0.076	BRCA2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
posterior lateral line neuromast hair cell development	1	5617.3×	0.005	TMEM132E
mitotic recombination-dependent replication fork processing	1	2808.7×	0.005	BRCA2
negative regulation of mammary gland epithelial cell proliferation	1	1123.5×	0.009	BRCA2
establishment of protein localization to telomere	1	702.2×	0.009	BRCA2
response to UV-C	1	561.7×	0.009	BRCA2
telomere maintenance via recombination	1	510.7×	0.009	BRCA2
regulation of DNA damage checkpoint	1	374.5×	0.010	BRCA2
inner cell mass cell proliferation	1	330.4×	0.010	BRCA2
centrosome duplication	1	312.1×	0.010	BRCA2
response to X-ray	1	295.6×	0.010	BRCA2
female gonad development	1	267.5×	0.010	BRCA2
hematopoietic stem cell proliferation	1	216.1×	0.010	BRCA2
oocyte maturation	1	200.6×	0.010	BRCA2
male meiosis I	1	193.7×	0.010	BRCA2
response to gamma radiation	1	193.7×	0.010	BRCA2
calcium ion import across plasma membrane	1	181.2×	0.010	NALF1
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	1	165.2×	0.010	BRCA2
positive regulation of mitotic cell cycle	1	156.0×	0.010	BRCA2
regulation of cytokinesis	1	140.4×	0.011	BRCA2
cellular response to ionizing radiation	1	137.0×	0.011	BRCA2
nucleotide-excision repair	1	127.7×	0.011	BRCA2
DNA damage response, signal transduction by p53 class mediator	1	119.5×	0.011	BRCA2
cellular senescence	1	98.5×	0.013	BRCA2
double-strand break repair	1	67.7×	0.018	BRCA2
double-strand break repair via homologous recombination	1	52.0×	0.022	BRCA2
brain development	1	26.5×	0.042	BRCA2
spermatogenesis	1	11.7×	0.089	BRCA2
regulation of DNA-templated transcription	1	10.5×	0.095	BRCA2
positive regulation of DNA-templated transcription	1	9.3×	0.104	BRCA2

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 4

Druggability breadth: 0 of 4 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRCA2	0	0
TMEM132E	0	0
NALF1	0	0
LINC00373	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	4	BRCA2, TMEM132E, NALF1, LINC00373

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	—
TMEM132E	0	—
NALF1	0	—
LINC00373	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.